Genmab

Jan van de Winkel, as President and CEO and a co-founder, has overseen the company's strategic direction since 1999. Investment decisions — including pipeline prioritization, platform licensing terms, and M&A — are executed by the management team under board oversight, consistent with Danish public-company governance. The December 2023 ProfoundBio acquisition and the BioNTech collaboration both originated from this centralized capital-allocation process.

Genmab operates as an IP originator and licensor, not a commercial manufacturer. For Darzalex, it granted Janssen exclusive worldwide rights in exchange for tiered royalties currently ranging from 12% to 20% of net sales. For Epkinly, AbbVie holds US/Japan commercialization rights while Genmab retains ex-US rights, splitting profits 50/50 in those territories. This model means Genmab carries no manufacturing plants for its lead drugs and no sales force for most markets.

Genmab primarily allocates capital to its own pipeline, platform technology, and bolt-on acquisitions such as the $1.8 billion ProfoundBio deal. It maintains a marketable securities portfolio from cash reserves, but the firm does not operate as a third-party allocator or fund-of-funds investor. Its external financial commitments are limited to corporate venture-style research collaborations rather than LP stakes in outside biotech funds.

Genmab focuses almost exclusively on oncology, with the notable exception of Kesimpta in multiple sclerosis. It has not pursued cardiovascular, metabolic, or central nervous system indications outside neurology. The firm's public pipeline and partnership roster shows no material activity in gene therapy, cell therapy, or vaccines — antibody-based biologics remain the organizing principle.

Royalty income from partnered commercial products funds a significant portion of R&D. Darzalex and Kesimpta alone generate cash flows that Genmab reinvests into its early- and mid-stage bispecific programs. This creates a self-sustaining funding loop that limits equity dilution. New partnerships — such as the BioNTech deal — bring additional milestone payments and cost-sharing, further protecting the balance sheet.

Genmab operates a Charitable Donations Program rather than a separate foundation. Donations are typically directed toward cancer research organizations and patient advocacy groups. The program is managed internally and does not hold assets or operate as an independent grant-making entity. There is no evidence of a donor-advised fund or a private foundation linked to the firm.

Genmab's partnership model is built around co-development cost-sharing rather than passive co-investment. In the AbbVie collaboration for Epkinly, Genmab shares commercial responsibilities and profit participation ex-US, while AbbVie funds US development in return for rights. The firm does not act as a limited partner in external venture funds or as a silent co-investor in other biotechs' rounds — partnership economics are tied directly to specific programs.